Pyrotinib Plus Vinorelbine in HER2+ Metastatic Breast Cancer Patients

Fudan University

Status: Completed

Conditions: Breast Cancer

Study type: Observational

Funder types: Other

Identifiers

NCT04517305

YOUNGBC-10

Details and patient eligibility

About

To evaluate the patterns and treatment outcomes of pyrotinib plus vinorelbine in the real world.

Enrollment: 97 patients

Sex: Female

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• woman, age > 18 years old
• diagnosed with HER2 +Metastatic Breast Cancer
• pyrotinib plus vinorelbine for at least one cycle, starting from 2018.05-2020.05
• available medical history

Exclusion criteria

• medical history was incomplete

Trial design

97 participants in 1 patient group

Pyrotinib plus vinorelbine

Description:

Patients used pyrotinib plus vinorelbine as treatment for metastatic breast cancer.